Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial

Kyoto University Substance (KUS) 121, an ATPase inhibitor of valosin-containing protein, is a novel neuroprotectant. We tested the safety and effectiveness of KUS121 in patients with acute central retinal artery occlusion (CRAO). We conducted an investigator-initiated, first-in-humans, phase 1/2 cli...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :PLoS One
Главные авторы: Ikeda, Hanako Ohashi, Muraoka, Yuki, Hata, Masayuki, Sumi, Eriko, Ikeda, Takafumi, Nakagawa, Takayuki, Abe, Hiroyasu, Tada, Harue, Morita, Satoshi, Kakizuka, Akira, Yoshimura, Nagahisa, Tsujikawa, Akitaka
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2020
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7018138/
https://ncbi.nlm.nih.gov/pubmed/32053676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0229068
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы